Gentherm (THRM) Q3 2024 earnings summary

Executive summary

• Product revenues for Q3 2024 increased 1.5% year-over-year to $371.5 million, with net income of $16.0 million and adjusted diluted EPS of $0.75, up from $0.64 in Q3 2023.

• Achieved $600 million in new automotive business awards in Q3, with 30 vehicle launches across 11 OEMs, including the first ClimateSense launch on Cadillac Escalade IQ and ComfortScale award with General Motors.

• Medical segment delivered double-digit revenue growth year-over-year, driven by Blanketrol and Astopad sales in the U.S. and Europe.

• Focused on operational execution, innovation, and margin expansion with proprietary products like ClimateSense, WellSense, and ComfortScale.

• Completed shutdown and sale of the South Carolina plant, consolidating production in Monterrey, Mexico, and contributing a $1.7 million gain.

Financial highlights

• Q3 product revenues were $371.5 million (up 1.5% year-over-year); nine-month revenues were $1.10 billion (up 0.1%).

• Gross margin improved to 25.5% from 23.5% year-over-year, aided by cost reductions and operational efficiencies.

• Adjusted EBITDA was $48.1 million (12.9% margin); operating income rose to $32.3 million from $23.7 million year-over-year.

• Adjusted diluted EPS was $0.75, up from $0.64 in Q3 2023; GAAP diluted EPS was $0.51.

• Cash and equivalents at quarter-end were $150.6 million; total liquidity $428.6 million.

Outlook and guidance

• 2024 product revenue guidance narrowed to $1.45–$1.47 billion, reflecting lower light vehicle production and supply chain adjustments.

• Adjusted EBITDA margin expected near midpoint of 12.5%–13.5%; capital expenditures guidance unchanged at $65M–$75M.

• Effective tax rate guidance 26%–29%; actual Q3 effective tax rate was approximately 18%.

• Management believes current liquidity and cash flows are adequate for at least the next twelve months.

• Guidance assumes light vehicle production in key markets will decline low to mid-single digits for 2024.